Document Detail

Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines.
MedLine Citation:
PMID:  20714358     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Rotavirus infection is the most common cause of severe gastroenteritis globally, with greater than 86% of deaths occurring in low-income and middle-income countries. There are two rotavirus vaccines currently licensed in the United States and prequalified by the World Health Organization. RV1 is a monovalent attenuated human rotavirus strain, given orally in two doses. RV5 is a pentavalent human-bovine reassortant rotavirus vaccine, given orally in three doses. A third rotavirus vaccine, LLV, is a lamb rotavirus strain given orally as a single dose, which is currently available only in China. RV1 and RV5 have been shown to be highly efficacious in developed countries, and initial results from trials in Africa and Asia are promising as well. At least three other vaccines are in development, which are being developed by manufacturers of developing countries. Further studies are needed to clarify issues including administration of oral rotavirus vaccines with breastfeeding and other oral vaccines, and alterations in dosing schedule. Using new data on global diarrheal burden, rotavirus is estimated to cause 390,000 deaths in children younger than 5 years. Should rotavirus vaccines be introduced in the routine immunization programs of all countries, a potential of 170,000 deaths could be prevented annually. The largest impact on mortality would be seen in low-income and middle-income countries, despite poor immunization coverage and lower efficacy. Therefore, international efforts are needed to ensure that rotavirus vaccines reach the populations with highest burden of rotavirus disease.
Aruna Chandran; Sean Fitzwater; Anjie Zhen; Mathuram Santosham
Related Documents :
16713038 - Use of national health insurance database to evaluate the impact of public varicella va...
19571648 - Herpes zoster and postherpetic neuralgia: a review of the effects of vaccination.
21921208 - Safety and immunogenicity of lc16m8, an attenuated smallpox vaccine in vaccinia-naive a...
19588778 - The incidence and clinical presentation of infantile rotavirus diarrhoea in sierra leone.
25492868 - Crystal structures of ev71 recombinant virus particles provide insights into vaccine de...
11583378 - Clostridium infection (jisizheng) in yaks in qinghai, china.
Publication Detail:
Type:  Journal Article     Date:  2010-08-09
Journal Detail:
Title:  Biologics : targets & therapy     Volume:  4     ISSN:  1177-5491     ISO Abbreviation:  Biologics     Publication Date:  2010  
Date Detail:
Created Date:  2010-08-17     Completed Date:  2011-07-14     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101321511     Medline TA:  Biologics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  213-29     Citation Subset:  -    
Department of International Health, Division of Health Systems.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast a...
Next Document:  New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride.